Newsletter | October 1, 2026

10.01.26 -- AI, Data Integrity, And Wireless Gaps Are Reshaping Trials

EDITOR’S TAKE: WHERE TRIAL DATA INTEGRITY REALLY BREAKS

Clinical AI Needs Proof, Not More Hype Or Promises

David Vulcano argues clinical research should report AI failures with adverse-event rigor. Learn why evidence and transparency must replace AI hype.

 

Why Wireless Failures Can Compromise Clinical Trial Data

Packet loss, multipath interference, and battery tradeoffs can undermine wearable data validity. Learn why wireless design is a scientific issue.

AI, DATA QUALITY, AND GOVERNANCE UNDER PRESSURE

Where Agentic AI Is Already Changing Clinical Trials (53 characters)

Leaders from AstraZeneca, Syneos Health, Sarah Cannon, and Medable share where agentic AI is delivering value in real clinical trial operations.

Who Owns AI Decisions In Clinical Trial Governance?

Clear ownership, shared policies, and aligned teams are essential for AI governance. Learn how to manage risk and support compliant innovation in trials.

Why Smart Sponsors Build Data Quality At The Source

Downstream data cleaning adds cost, delays, and risk. Learn how designing quality at the source reduces errors and strengthens trial execution.

Why Phase I Oncology Trials Should Start With eCOA

Phase I oncology teams can collect meaningful patient outcomes data without added complexity, creating a stronger foundation for later-phase eCOA use.

How AI Is Changing HEOR Evidence And Outcomes Research

Explore how AI is changing HEOR, from faster evidence generation to stronger insights that support healthcare value, outcomes, and decisions.

TOOLS FOR BETTER DATA CAPTURE AND GLOBAL TRIAL DELIVERY

Visit Management For More Reliable Global Trial Delivery

Expand Trial Data Capture Without Adding Site Burden